Protease inhibitors (gabexate 74% and urinastatin 21%) were administered as a treatment for severe acute pancreatitis and/or DIC, and
antithrombin III preparation (51%) and rTM (34%) were used for DIC.
The stakeholders of this report include companies and intermediaries engaged in the manufacture, commercialization, providing services of ant thrombin products such as
Antithrombin III, ATryn, and Antithrombin Gama and others as well as new entrants planning to enter this market.
Unfavorable genetic background increases the risk of CVT:
antithrombin III deficiency, protein C, protein S, factor V or II mutation, activated protein C resistance, mutations in the methylenetetrahydrofolate reductase (MTHFR) gene.
White blood cell (WBC) count, CRP, hs-CRP, procalcitonin, fibrinolytic system markers including DD, FDPs, fibrin monomers, and natural anticoagulant proteins such as protein C, protein S, and
antithrombin III were investigated by means of the blood samples.
Contract award notice: Fviii preparation and
antithrombin iii concentrate (hungary-budapest: Antihaemorrhagics)
Hypercoagulable laboratory studies were normal, including anticardiolipin antibody IgG and IgM, factor V Leiden, prothrombin G20210A mutation, thrombin time,
antithrombin III, and protein C and S activity.
A thrombophilia screen, including anticardiolipin antibodies, proteins S and C, activated protein C resistance,
antithrombin III, and erythrocyte sedimentation rate, was normal.
Mesenteric vein thrombosis is an uncommon disease associated with acute abdomen, and many risk factors have been identified such as intra-abdominal or hematological causes, patent or latent myeloproliferative syndrome, protein C or S, and
antithrombin III or plasminogen activator deficiencies.[1] Unfortunately, no obvious etiology could be identified for this case in spite of intensive examinations.
[3] Other causes include dehydration, polycythaemia, reduced renal blood flow due to shock and hyperosmolality, congenital heart disease and deficiency of anticoagulants like protein C and S,
Antithrombin III, factor V Leiden mutation and prothrombin mutation.
Laboratory investigations showed normal CBC, PT/APTT and Protein S level while Protein C and
Antithrombin III levels were low.
The relevant hematological and autoimmune work-up includes testing for ANA, ANCA, anti-ds-DNA, anti-Sm, antiphospholipid antibodies, anticardiolipin antibodies, protein C, protein S,
antithrombin III, and homocysteine.
Thrombophilia screen including Protein C, Protein S,
Antithrombin III, APC Resistance-V, Factor VIII, homocysteine, and Anticardiolipin antibodies was performed which was negative.
